MarketResearchReports.Biz

Global Radio Pharmaceutical Market to Grow at a CAGR of 18.39 Percent over the Period 2012-2016.

MarketResearchReports.Biz presents this most up-to-date research on "Global Radio Pharmaceutical market to grow at a CAGR of 18.39 percent over the period 2012-2016."

 
Repost This

Albany, NY -- (SBWIRE) -- 12/24/2013 -- Global Radio Pharmaceutical market to grow at a CAGR of 18.39 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing aging population. The Global Radio Pharmaceutical market has also been witnessing the increasing demand for radiopharmaceuticals. However, the short half-life could pose a challenge to the growth of this market.
TechNavio's report, the Global Radio Pharmaceutical Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Radio Pharmaceutical market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The key vendors dominating this market space are Cardinal Health Inc., Covidien plc, Lantheus Medical Imaging Inc., and IBA Molecular Inc.

To check out the complete table of contents, visit: http://www.marketresearchreports.biz/analysis-details/global-radiopharmaceutical-market-2012-2016

Other vendors mentioned in the report are Advanced Medical Isotope Corp., Advanced Accelerator Applications SA, Algeta ASA, Bio-Nucleonics Inc., GE Healthcare Ltd., Monrol Nuclear Products Inc., Molecular Insight Pharmaceuticals Inc., Nordion Inc., Novelos Therapeutics Inc., NTP Radioisotopes (Pty) Ltd., Positron Corp., and Siemens Healthcare.
Key questions answered in this report:
What will the market size be in 2016 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.

Table Of Contents

01. Executive Summary
02. Scope of the Report
02.1 Market Overview
02.2 Product Offerings
03. Market Research Methodology
03.1 Market Research Process
03.2 Research Design
03.3 Research Methodology
04. List of Abbreviations
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis

Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/179217

07. Global Radiopharmaceuticals Market Segmentation by Application
07.1 Global Diagnostic Radiopharmaceuticals Market
07.1.1 Market Size and Forecast
07.2 Global Therapeutics Radiopharmaceuticals Market
07.2.1 Market Size and Forecast
08. Geographical Segmentation
09. Key Leading Countries
09.1 US
09.2 Germany
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.1.2 Mergers and Acquisitions
17.2 Market Share Analysis 2012
17.3 Other Prominent Vendors
18. Key Vendor Analysis
18.1 Covidien plc
18.1.1 Business Overview
18.1.2 Business Segmentation
18.1.3 Key Information
18.1.4 SWOT Analysis
18.2 Cardinal Health Inc.
18.2.1 Business Overview
18.2.2 Business Segmentation
18.2.3 Key Information
SWOT Analysis
18.3 IBA Molecular Inc.
18.3.1 Business Overview
18.3.2 Business Segmentation
18.3.3 Key Information
18.3.4 SWOT Analysis
18.4 Lantheus Medical Imaging Inc.
18.4.1 Business Overview
18.4.2 Key Information
18.4.3 SWOT Analysis

To Buy The Copy of This Report Visit: http://www.marketresearchreports.biz/analysis/179217

19. Other Reports in this Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Radiopharmaceuticals Market 2012-2016 (US $ billion)
Exhibit 3: Global Radiopharmaceuticals Market Segmentation by Application
Exhibit 4: Global Radiopharmaceuticals Market Segmentation Based on Application 2012
Exhibit 5: Global Radiopharmaceuticals Market Segmentation Based on Application 2016
Exhibit 6: Global Diagnostic Radiopharmaceuticals Market 2012-2016 (US$ billion)
Exhibit 7: Global Therapeutics Radiopharmaceuticals Market 2012-2016 (US$ billion)
Exhibit 8: Global Radiopharmaceuticals Market by Geographical Segmentation 2012
Exhibit 9: Global Radiopharmaceuticals Market by Vendor Segmentation 2012
Exhibit 10: Business Segmentation of Covidien plc
Exhibit 11: Business Segmentation of Cardinal Healthcare Inc.
Exhibit 12: Business Segmentation of IBA Molecular Inc.

Latest Reports:

Infectious Vaccines Partnering Terms and Agreements: http://www.marketresearchreports.biz/analysis-details/infectious-vaccines-partnering-terms-and-agreements

The Infectious Vaccines Partnering Terms and agreements report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

This report provides details of the latest infectious vaccines agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2007, including financial terms where available, including over 700 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/180295

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What are the precise rights granted or optioned?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?

Alzheimers Pipeline Drugs Review, Alzheimers Disease Drug Market & Forecast - Global Analysis: http://www.marketresearchreports.biz/analysis-details/alzheimers-pipeline-drugs-review-alzheimers-disease-drug-market-and-forecast-global-analysis

Alzheimer’s disease drug market is on the curvature stage. Since 2003, there is not any single “magic bullet” launched in the market to prevent or cure it. However, all current marketed products are going to be generic in the next 3-4 years. There are high unmet medical needs. The current unmet needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel therapies. If successful, they will be in a position to command premium prices and tap the existing opportunity. Lot of drugs has failed in Phase III stage thus putting a greater impact on Alzheimer’s disease drug market.

From the year 2009 Alzheimer’s disease drug market is declining and it is expected to fall till 2016. But with the expected launch of some Alzheimer’s drugs from the year 2017 onwards, Alzheimer’s disease drug market is expected to revive in the coming years. However due to absence of exact potential drugs there will always remain a huge Unmet Alzheimer’s Drug Market. For the year 2018 Alzheimer’s Disease Drug Market will be just 10% of Unmet Alzheimer’s Disease Drug Market.

Renub Research study titled “Alzheimer’s Pipeline Drugs Review, Alzheimer’s Disease Drug Market & Forecast – Global Analysis” provides a comprehensive assessment of the fast-evolving, high-growth Global Alzheimer’s Disease Market. This 110 page report with 29 Figures and 11 Tables studies the Global Alzheimer’s Disease Drug Market.

Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/180278

Present & Pipeline Drugs Studied in this Report

1. Namenda
2. Ebixa
3. Axura
4. Aricept
5. Nootropil
6. Exelon
7. Memary
8. Solanezumab
9. LuAe58054
This report contains 10 chapters.

(Chapter 1): Executive Summary

(Chapter 2): This Chapter is divided into 2 parts

A. Alzheimer’s Disease Drug Market & Forecast data available from 2003 to 2018

B. Unmet Alzheimer’s Disease Drug Market & Forecast (Market Potential) data available from 2010 to 2018. (Unmet market is the potential market which could have been achieved if right drug have been introduced in the market)

(Chapter 3): This chapter talks about drugs which has failed while in Clinical trials

(Chapter 4): This chapter provides Market Share of Alzheimer’s Disease Drug from 2003 to 2018. All the 9 Alzheimer’s drug mentioned above have been covered in this chapter.

About MarketResearchReports.Biz
MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/